1 / 41

The Complex Ethics of Academic-Industry Collaborations

The Complex Ethics of Academic-Industry Collaborations . Ross McKinney, Jr , MD Duke University School of Medicine. Outline. What is Conflict of Interest? (COI) Areas of Concern Federal rule changes Duke processes. Don’t get the wrong message.

kaia
Download Presentation

The Complex Ethics of Academic-Industry Collaborations

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. The Complex Ethics of Academic-Industry Collaborations Ross McKinney, Jr, MD Duke University School of Medicine

  2. Outline • What is Conflict of Interest? (COI) • Areas of Concern • Federal rule changes • Duke processes

  3. Don’t get the wrong message • In health care, almost no good idea will affect significant number of patients if it isn’t commercialized • Pharmaceutical & device companies don’t take care of patients – they need advice from people who do • Conflict of interest isn’t intrinsically bad – it’s a normal part of life • At Duke, we encourage working with industry (as distinct from for industry)

  4. But… • Professionalism means putting the interests of your patients above your own self-interest • In research, professionalism means putting your science above your self-interests • Economic (promotion, salary, grants) • Social (status) • Identification with an idea • We need to educate, but we should do so without marketing (e.g. CME v. speakers bureaus)

  5. Definition - COI • A conflict of interest exists when a primary interest or responsibility is (unduly) affected by a secondary interest or responsibility

  6. Real World Examples • Dental work • Devils and Tar Heels

  7. Example An obvious charge - ignored...

  8. Key to the Example • Our perception is flavored by pre-set expectations and rationalizations of which we may not be aware • The whole crowd saw the same data, but drew very different conclusions

  9. COI is part of every day life • Human beings are very aware of COIs • Every sales encounter • All fee-for-service medical encounters

  10. The Human Response • We consider the paradigm, past history • We consider the secondary influences we can identify • Can we trust the provider? • If we break that trust as medical providers, what happens? • Decreased adherence / worse outcomes • Poor word-of-mouth • Malpractice cases

  11. Be Aware • The public is paying increasing attention to examples of physicians appearing to act in self interest instead of the best interest of their patients • Should we collectively care?

  12. A few industries • Airlines • Pharmaceuticals • Banking (71% trust in 2008 to 25% in 2011) • If people don’t respect and value physicians, will Congress use Medicare (i.e. physician payments) to balance the budget?

  13. Areas of Concern • Clinical Research • Clinical Care • Education • Commercialization of ideas

  14. Concerns: In Clinical Research • In science, reproducibility is the key test for validation • In clinical research, trials are often too expensive to reproduce • Don’t want to put people at risk unnecessarily • Primary means of validation is audit • Audit is not generally effective as a means to identify bias

  15. Goals of COI Management in Research • Protect research subjects from biased decisions by conflicted investigators • Scientific integrity • Do not want clinical decisions based on data from biased studies • Don’t want conflicted investigators interpreting data • Role of the Academic as the fair-broker • Free of bias (at least financial)

  16. JAMA – 2003 – Als-Nielsen, et al • 370 randomized trials • Considered: 1) Outcome of trial; 2) Sponsor • Non-profit Sponsor - 16% recommended experimental drug as treatment of choice • Funding not reported: 30% • Mixed funding: 35% • For-profit organization: 51% • Difference significant (p<0.001)OR: 5.3; 95% CI 2.0-14.4)

  17. NEJM Study - 2008 • Studies of 12 anti-depressants, 12,564 patients • 38 studies with positive FDA results, of which 37 were published, 1 not published • 36 with negative FDA results • 3 published, 22 not published • 11 published with data selection to appear positive • In literature, 94% of publications were positive • Turner: NEJM 2008;258:252-260

  18. Merck’s ADVANTAGE study - 2003 • ADVANTAGE study: Assessment of Differences between Vioxxand Naproxynto Ascertain Gastrointestinal Tolerance and Efficacy • After 3 months, 27% more people stopped taking Naproxyn than Vioxx

  19. Brief Illustration • After 3 months, 27% more people stopped taking Naproxyn • Of course, that was 5.9% vs 8.1%

  20. Brief Illustration • After 3 months, 27% more people stopped taking Naproxyn • Of course, that was 5.9% vs 8.1%

  21. Brief Illustration • or better, 94% vs 92% tolerance

  22. Seeding Study • ADVANTAGE was designed by the marketing department at Merck • Real subjects were the MDs • Did use of study increase prescription rate? • Complimented enrolling doctors • Used many primary care sites, rather than a few high enrolling centers

  23. Brief Illustration • Personal experience – cost difference to me was 30x ($150 vs $5) [actually Celebrex vs ibuprofen] • Points like this have Congress’s eye as potential cost savings & unnecessary expenses • Migrate decision making from physicians to non-experts because of failure of physicians to perform the work of an expert adequately

  24. The Complicated Question • Bayh-Dole Act of 1980 • Inventions • Personal and institutional conflict • Safety concerns increase in import • The “rebuttable presumption” • Where’s the right balance?

  25. Concerns: In Clinical Care • The fee for service model • Note articles about inappropriate use of open breast biopsies (vs. needle), stenting of chronic stable angina, of spine surgery, of in-house diagnostic and treatment devices, of infusion therapies where the primary beneficiary seems to be the infuser rather than the infused • Insertion of flawed devices by physician developers and advocates • Routine procedures with reimbursement (EKGs, etc)

  26. Concerns: In Education • FDA Rules about talking off label • Speaker’s bureaus • If you know someone is being paid to give a talk, does it change your perception of the message?

  27. Concerns: In Education • FDA Rules about talking off label • Speaker’s bureaus • If you know someone is being paid to give a talk, does it change your perception of the message? • What if it’s true, but you don’t know?

  28. Physician Sunshine Act • Section 6002 of the Affordable Care Act • As of January 2012, pharmaceutical and device manufacturers must report all gifts and payments to physicians and teaching hospitals to a federal database • Threshold is $10 per item, or $100 per year • Results will be published in 2013 in a web based, searchable format

  29. Public awareness • What will the ramifications be of public disclosure? • An example, using the fact Minnesota has had a public database for several years

  30. New York Times article • Front Page – May 10, 2007 • “Psychiatrists, Children and Drug Industry’s Role” • “When Anya Bailey developed an eating disorder after her 12th birthday, her mother took her to a psychiatrist at the University of Minnesota who prescribed a powerful antipsychotic drug called Risperdal.”

  31. The problem • Anya gained weight but within two years developed a crippling knot in her back. She now receives regular injections of Botox to unclench her back muscles. She often awakens crying in pain.

  32. The COI • In 2003, the year Anya came to his clinic, Dr. Realmuto earned $5,000 from Johnson & Johnson for giving three talks about Concerta.

  33. The COI • In 2003, the year Anya came to his clinic, Dr. Realmuto earned $5,000 from Johnson & Johnson for giving three talks about Concerta. • However, not clever to say – • “Academics don’t get paid very much. If I was an entertainer, I think I would certainly do a lot better.”

  34. The COI • In 2003, the year Anya came to his clinic, Dr. Realmuto earned $5,000 from Johnson & Johnson for giving three talks about Concerta. • However, not clever to say – • “Academics don’t get paid very much. If I was an entertainer, I think I would certainly do a lot better.” • (Dr. Realmuto’s university salary is $196,310.)

  35. Minnesota case • Was it really the result of COI? • Amount of money was small • Adverse events happen • Perception of outsiders may differ from our own • Malpractice attorneys eagerly awaiting the federal database

  36. The role of gifts • Duke rules prohibit gifts, including meals, from pharmaceutical and device reps • Unrestricted educational grants to the institution are allowed • True CME can be supported – no quid pro quo allowed • Gifts are a part of relationship building • Reps goal is to convert the relationship from a business one to a personal one • Airline example

  37. NIH Rules Recently Changed • $5,000 threshold for management and reporting to the NIH • All cases of FCOI of $5K or more. • Must report all sponsored travel (other than government, universities, and medical centers) • Require review of all personal FCOIs prior to any NIH grant expenditures (even on renewal) • Web site to post all FCOIs linked to grants (perhaps)

  38. Process • Annual report in March • Review (in order) • Review each grant application • Review IRB submissions • Review each grant award • Now consider purchasing, research, and (to a degree) clinical issues

  39. Limits • Require annual reporting of all relationships >$600/year (likely to except universities, academic medical centers, government, and research institutes) • As of January 1, management at $5K/year if there is an overlap with research • At $25K/year, can no longer be PI on related research

  40. Other limits • Treat equity as if it’s payments ($20,000 in stock is the same as $20,000 in payments) • Non-publically traded equity is treated as >$25K • Stock options are treated as >$25K • We look at royalty arrangements case-by-case

  41. Summary • Conflict of Interest is present in everyday life • Providing transparency is critical • Public perception may different from the insider’s view • If we want to remain professionals, we need to maintain the interests of our patients first

More Related